Summit Therapeutics Inc.
Price Action
Technical Summary
WEAKENINGSummit Therapeutics Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 26), showing significant lag compared to the market leaders. Earnings contraction of 167% provides fundamental context to the price action. Investors should exercise caution due to high volatility (83% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $21.26 | -16.03% | BELOW |
| 50 SMA | $18.45 | -3.24% | BELOW |
| 100 SMA | $17.54 | +1.75% | ABOVE |
| 150 SMA | $18.07 | -1.22% | BELOW |
| 200 SMA | $19.57 | -8.81% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SMMT in an uptrend right now?
SMMT has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is SMMT overbought or oversold?
SMMT's RSI (14) is 41. The stock is in neutral territory, neither overbought nor oversold.
Is SMMT outperforming the market?
SMMT has a Relative Strength (RS) Rating of 26 out of 99. SMMT is currently lagging the broader market.
Where is SMMT in its 52-week range?
SMMT is trading at $17.85, which is 58% of its 52-week high ($30.98) and 23% above its 52-week low ($13.83).
How volatile is SMMT?
SMMT has a Beta of 1.89 and 52-week volatility of 83%. It's more volatile than the S&P 500 - expect bigger swings.